CC BY 4.0 · Arq Neuropsiquiatr 2023; 81(03): 308-321
DOI: 10.1055/s-0043-1764412
Brazilian Academy of Neurology

Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition

Consenso brasileiro para o diagnóstico, manejo e tratamento da polineuropatia amiloidótica familiar associada à transtirretina: segunda edição
Marcus Vinicius Pinto 
1   Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello, Rio de Janeiro RJ, Brazil.
2   Mayo Clinic, Department of Neurology, Rochester, Minnesota, United States.
,
Marcondes Cavalcante França  Jr
3   Universidade de Campinas, Faculdade de Ciências Médicas, Campinas SP, Brazil.
,
Marcus Vinicius Magno Gonçalves 
4   Universidade Univalle, Joinville SC, Brazil.
,
Marcela Câmara Machado-Costa 
5   Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil.
,
Marcos Raimundo Gomes de Freitas 
1   Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello, Rio de Janeiro RJ, Brazil.
,
Francisco de Assis Aquino Gondim 
6   Universidade Federal do Ceará, Faculdade de Medicina, Fortaleza CE, Brazil.
,
Carlo Domenico Marrone 
7   Pontifícia Universidade Católica do Rio Grande do Sul, Hospital São Lucas, Clínica Marrone e Ambulatório de Doenças Neuromusculare, Porto Alegre RS, Brazil.
,
Alberto Rolim Muro Martinez 
3   Universidade de Campinas, Faculdade de Ciências Médicas, Campinas SP, Brazil.
,
Carolina Lavigne Moreira 
8   Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto SP, Brazil.
,
Osvaldo J. M. Nascimento 
9   Universidade Federal Fluminense, Niterói RJ, Brazil.
,
Anna Paula Paranhos Covaleski 
10   Universidade Federal de Pernambuco, Hospital das Clínicas, Recife PE, Brazil.
,
Acary Souza Bulle de Oliveira 
11   Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil.
,
Camila Castelo Branco Pupe 
9   Universidade Federal Fluminense, Niterói RJ, Brazil.
,
Marcia Maria Jardim Rodrigues 
12   Fundação Oswaldo Cruz, Rio de Janeiro RJ, Brazil.
,
Francisco Tellechea Rotta 
13   Hospital Moinhos de Vento, Porto Alegre RS, Brazil.
14   Santa Casa de Misericórdia de Porto Alegre, Porto Alegre RS, Brazil.
,
Rosana Herminia Scola 
15   Universidade Federal do Paraná, Faculdade de Medicina, Curitiba PR, Brazil.
,
Wilson Marques  Jr
8   Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto SP, Brazil.
,
Márcia Waddington-Cruz 
1   Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello, Rio de Janeiro RJ, Brazil.
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Hereditary transthyretin amyloidosis with peripheral neuropathy (ATTRv-PN) is an autosomal dominant inherited sensorimotor and autonomic polyneuropathy with over 130 pathogenic variants identified in the TTR gene. Hereditary transthyretin amyloidosis with peripheral neuropathy is a disabling, progressive and life-threatening genetic condition that leads to death in ∼ 10 years if untreated. The prospects for ATTRv-PN have changed in the last decades, as it has become a treatable neuropathy. In addition to liver transplantation, initiated in 1990, there are now at least 3 drugs approved in many countries, including Brazil, and many more are being developed. The first Brazilian consensus on ATTRv-PN was held in the city of Fortaleza, Brazil, in June 2017. Given the new advances in the area over the last 5 years, the Peripheral Neuropathy Scientific Department of the Brazilian Academy of Neurology organized a second edition of the consensus. Each panelist was responsible for reviewing the literature and updating a section of the previous paper. Thereafter, the 18 panelists got together virtually after careful review of the draft, discussed each section of the text, and reached a consensus for the final version of the manuscript.

Resumo

Polineuropatia amiloidótica familiar associada a transtirretina (ATTRv-PN) é uma polineuropatia sensitivo-motora e autonômica hereditária autossômica dominante com mais de 130 variantes patogênicas já identificadas no gene TTR. A ATTRv-PN é uma condição genética debilitante, progressiva e que ameaça a vida, levando à morte em ∼ 10 anos se não for tratada. Nas últimas décadas, a ATTRv-PN se tornou uma neuropatia tratável. Além do transplante de fígado, iniciado em 1990, temos agora 3 medicamentos modificadores de doença aprovados em muitos países, incluindo o Brasil, e muitas outras medicações estão em desenvolvimento. O primeiro consenso brasileiro em ATTRv-PN foi realizado em Fortaleza em junho de 2017. Devido aos novos avanços nesta área nos últimos 5 anos, o Departamento Científico de Neuropatias Periféricas da Academia Brasileira de Neurologia organizou uma segunda edição do consenso. Cada panelista ficou responsável por rever a literatura e atualizar uma parte do manuscrito. Finalmente, os 18 panelistas se reuniram virtualmente após revisão da primeira versão, discutiram cada parte do artigo e chegaram a um consenso sobre a versão final do manuscrito.

Keywords

Amyloidosis - Peripheral Nervous System Diseases - Amyloid Neuropathies, Familial

Palavras-chave

Amiloidoses - Doenças do Sistema Nervoso Periférico - Neuropatias Amiloides Familiares

Authors' Contibutions

MVP, MVG, MCFJ: original draft, manuscript review and editing, these authors contributed equally to this work as co-first authors; WMJ and MWC: manuscript review, editing and supervision, these authors contributed equally to this work as co-senior authors; The other authors contributed equally to the writing of the manuscript, review and editing.




Publication History

Received: 17 October 2022

Accepted: 27 October 2022

Article published online:
14 April 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu Rev Biochem 2017; 86: 27-68
    CrossrefPubMedGoogle Scholar
  • 2 Benson MD, Buxbaum JN, Eisenberg DS. et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25 (04) 215-219
    CrossrefPubMedGoogle Scholar
  • 3 Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36 (04) 411-423
    CrossrefPubMedGoogle Scholar
  • 4 Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10 (12) 1086-1097
    CrossrefPubMedGoogle Scholar
  • 5 Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 2019; 15 (07) 387-404
    CrossrefPubMedGoogle Scholar
  • 6 Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 126 (10) 1286-1300
    CrossrefPubMedGoogle Scholar
  • 7 Adams D, Ando Y, Beirão JM. et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 2021; 268 (06) 2109-2122
    CrossrefPubMedGoogle Scholar
  • 8 Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care. Ther Clin Risk Manag 2020; 16: 109-123
    CrossrefPubMedGoogle Scholar
  • 9 Adams D, Samuel D, Goulon-Goeau C. et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123 (Pt 7): 1495-1504
    CrossrefPubMedGoogle Scholar
  • 10 Coelho T, Maia LF, Martins da Silva A. et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79 (08) 785-792
    CrossrefPubMedGoogle Scholar
  • 11 Berk JL, Suhr OB, Obici L. et al; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310 (24) 2658-2667
    CrossrefPubMedGoogle Scholar
  • 12 Adams D, Gonzalez-Duarte A, O'Riordan WD. et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 2018; 379 (01) 11-21
    CrossrefPubMedGoogle Scholar
  • 13 Benson MD, Waddington-Cruz M, Berk JL. et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 2018; 379 (01) 22-31
    CrossrefPubMedGoogle Scholar
  • 14 Pinto MV, Barreira AA, Bulle AS. et al. Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arq Neuropsiquiatr 2018; 76 (09) 609-621
    CrossrefPubMedGoogle Scholar
  • 15 Ando Y, Coelho T, Berk JL. et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013; 8: 31
    CrossrefPubMedGoogle Scholar
  • 16 Schmidt H, Cruz MW, Botteman MF. et al. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. Amyloid 2017; 24 (sup1): 111-112
    CrossrefPubMedGoogle Scholar
  • 17 Parman Y, Adams D, Obici L. et al; European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 2016; 29 (Suppl 1, Suppl 1) S3-S13
    CrossrefPubMedGoogle Scholar
  • 18 Inês M, Coelho T, Conceição I, Duarte-Ramos F, de Carvalho M, Costa J. Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study. Neuroepidemiology 2018; 51 3-4 177-182
    CrossrefPubMedGoogle Scholar
  • 19 Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA 2020; 324 (01) 79-89
    CrossrefPubMedGoogle Scholar
  • 20 Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995; 60 (06) 512-521
    CrossrefPubMedGoogle Scholar
  • 21 Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15 (03) 181-186
    CrossrefPubMedGoogle Scholar
  • 22 Planté-Bordeneuve V, Carayol J, Ferreira A. et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003; 40 (11) e120
    CrossrefPubMedGoogle Scholar
  • 23 Saporta MA, Zaros C, Cruz MW. et al. Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families. Eur J Neurol 2009; 16 (03) 337-341
    CrossrefPubMedGoogle Scholar
  • 24 Waddington-Cruz M, Schmidt H, Botteman MF. et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis 2019; 14 (01) 34
    CrossrefPubMedGoogle Scholar
  • 25 Schmidt HWC. M.; Botteman, M.F.; Carter, J.A.; Chopra, A.S.; Stewart, M.; Hopps, M.; Fallet, S.; Amass, L. Global prevalence estimates of transthyretin familial amyloid polyneuropathy (ATTR-FAP): a systematic review and projections. The 19th annual European Congress of International Society for Pharmacoeconomics and Outcomes Research. Vienna, Austria2016
    Google Scholar
  • 26 Lavigne-Moreira C, Marques VD, Gonçalves MVM. et al. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population. J Peripher Nerv Syst 2018; 23 (02) 134-137
    CrossrefPubMedGoogle Scholar
  • 27 Misu Ki, Hattori N, Nagamatsu M. et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain 1999; 122 (Pt 10): 1951-1962
    CrossrefPubMedGoogle Scholar
  • 28 Sobue G, Nakao N, Murakami K. et al. Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system. Brain 1990; 113 (Pt 4): 903-919
    CrossrefPubMedGoogle Scholar
  • 29 Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86 (09) 1036-1043
    CrossrefPubMedGoogle Scholar
  • 30 Sekijima Y. Hereditary Transthyretin Amyloidosis: University of Washington, Seattle, Seattle (WA), 1993
    PubMed
  • 31 Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001; 293 (5539): 2459-2462
    CrossrefPubMedGoogle Scholar
  • 32 Bonaïti B, Olsson M, Hellman U, Suhr O, Bonaïti-Pellié C, Planté-Bordeneuve V. TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?. Eur J Hum Genet 2010; 18 (08) 948-952
    CrossrefPubMedGoogle Scholar
  • 33 Koike H, Misu K, Ikeda S. et al; Study Group for Hereditary Neuropathy in Japan. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002; 59 (11) 1771-1776
    CrossrefPubMedGoogle Scholar
  • 34 Benson MD, Dasgupta NR, Rao R. Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines. Ther Clin Risk Manag 2020; 16: 749-758
    CrossrefPubMedGoogle Scholar
  • 35 Thomas VE, Smith J, Benson MD, Dasgupta NR. Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease. Neurodegener Dis Manag 2019; 9 (06) 289-299
    CrossrefPubMedGoogle Scholar
  • 36 Cruz MW, Pinto MV, Pinto LF. et al. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS). Arq Neuropsiquiatr 2019; 77 (02) 96-100
    CrossrefPubMedGoogle Scholar
  • 37 Jacobson DR, Pastore R, Pool S. et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996; 98 (02) 236-238
    CrossrefPubMedGoogle Scholar
  • 38 Coutinho PDA, Lima JL, Barbosa AR. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: Glenner GG CP, de Freitas AF. ed. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980: 88-98
    Google Scholar
  • 39 Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid 2012; 19 (Suppl 1): 65-67
    CrossrefPubMedGoogle Scholar
  • 40 Bittencourt PL, Couto CA, Clemente C. et al. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol 2005; 12 (04) 289-293
    CrossrefPubMedGoogle Scholar
  • 41 Pinto MV, Pinto LF, Dias M. et al. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry. J Neurol Sci 2019; 403: 1-6
    CrossrefPubMedGoogle Scholar
  • 42 Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007; 35 (01) 116-118
    CrossrefPubMedGoogle Scholar
  • 43 Mariani LL, Lozeron P, Théaudin M. et al; French Familial Amyloid Polyneuropathies Network (CORNAMYL) Study Group. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015; 78 (06) 901-916
    CrossrefPubMedGoogle Scholar
  • 44 Koike H, Tanaka F, Hashimoto R. et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012; 83 (02) 152-158
    CrossrefPubMedGoogle Scholar
  • 45 Dohrn MF, Röcken C, De Bleecker JL. et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013; 260 (12) 3093-3108
    CrossrefPubMedGoogle Scholar
  • 46 Swiecicki PL, Zhen DB, Mauermann ML. et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid 2015; 22 (02) 123-131
    CrossrefPubMedGoogle Scholar
  • 47 Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75 (03) 408-427
    PubMedGoogle Scholar
  • 48 Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62 (07) 1057-1062
    CrossrefPubMedGoogle Scholar
  • 49 Coelho T, Sousa A, Lourenço E, Ramalheira J. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet 1994; 31 (04) 293-299
    CrossrefPubMedGoogle Scholar
  • 50 Ikeda S, Hanyu N, Hongo M. et al. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain 1987; 110 (Pt 2): 315-337
    CrossrefPubMedGoogle Scholar
  • 51 Adams D, Lozeron P, Theaudin M. et al; French Network for FAP. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 2012; 19 (Suppl 1): 61-64
    CrossrefPubMedGoogle Scholar
  • 52 Rapezzi C, Quarta CC, Riva L. et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010; 7 (07) 398-408
    CrossrefPubMedGoogle Scholar
  • 53 Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail 2019; 6 (06) 1128-1139
    CrossrefPubMedGoogle Scholar
  • 54 Maurer MS, Hanna M, Grogan M. et al; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016; 68 (02) 161-172
    CrossrefPubMedGoogle Scholar
  • 55 Garcia-Pavia P, Rapezzi C, Adler Y. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021; 42 (16) 1554-1568
    CrossrefPubMedGoogle Scholar
  • 56 Queiroz MC, Pedrosa RC, Berensztejn AC. et al. Frequency of Cardiovascular Involvement in Familial Amyloidotic Polyneuropathy in Brazilian Patients. Arq Bras Cardiol 2015; 105 (05) 503-509
    PubMedGoogle Scholar
  • 57 Gillmore JD, Maurer MS, Falk RH. et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016; 133 (24) 2404-2412
    CrossrefPubMedGoogle Scholar
  • 58 Simões MV, Fernandes F, Marcondes-Braga FG. et al. Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021. Arq Bras Cardiol 2021; 117 (03) 561-598
    CrossrefPubMedGoogle Scholar
  • 59 Yamashita T, Ando Y, Katsuragi S. et al. Muscular amyloid angiopathy with amyloidgenic transthyretin Ser50Ile and Tyr114Cys. Muscle Nerve 2005; 31 (01) 41-45
    CrossrefPubMedGoogle Scholar
  • 60 Pinto MV, Milone M, Mauermann ML. et al. Transthyretin amyloidosis: Putting myopathy on the map. Muscle Nerve 2020; 61 (01) 95-100
    CrossrefPubMedGoogle Scholar
  • 61 Pinto MV, Dyck PJB, Liewluck T. Neuromuscular amyloidosis: Unmasking the master of disguise. Muscle Nerve 2021; 64 (01) 23-36
    CrossrefPubMedGoogle Scholar
  • 62 Ando E, Ando Y, Okamura R, Uchino M, Ando M, Negi A. Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Br J Ophthalmol 1997; 81 (04) 295-298
    CrossrefPubMedGoogle Scholar
  • 63 Gondim FAA, Holanda Filha JG, Moraes Filho MO. Ophthalmological manifestations of hereditary transthyretin amyloidosis. Arq Bras Oftalmol 2022; 85 (05) 528-538
    PubMedGoogle Scholar
  • 64 Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012; 7 (08) 1337-1346
    CrossrefPubMedGoogle Scholar
  • 65 Ikeda SI, Hineno A, Ichikawa T, Makino M. Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis. Amyloid 2019; 26 (02) 99-100
    CrossrefPubMedGoogle Scholar
  • 66 Maia LF, Magalhães R, Freitas J. et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry 2015; 86 (02) 159-167
    CrossrefPubMedGoogle Scholar
  • 67 Sousa L, Coelho T, Taipa R. CNS Involvement in Hereditary Transthyretin Amyloidosis. Neurology 2021; 97 (24) 1111-1119
    CrossrefPubMedGoogle Scholar
  • 68 Quintanilha GS, Cruz MW, Silva MTT, Chimelli L. Oculoleptomeningeal Amyloidosis Due to Transthyretin p.Y89H (Y69H) Variant. J Neuropathol Exp Neurol 2020; 79 (10) 1134-1136
    CrossrefPubMedGoogle Scholar
  • 69 Conceição I, González-Duarte A, Obici L. et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2016; 21 (01) 5-9
    CrossrefPubMedGoogle Scholar
  • 70 Adams D, Suhr OB, Hund E. et al; European Network for TTR-FAP (ATTReuNET). First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016; 29 (Suppl 1, Suppl 1) S14-S26
    CrossrefPubMedGoogle Scholar
  • 71 Vital C, Vital A, Bouillot-Eimer S, Brechenmacher C, Ferrer X, Lagueny A. Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. J Peripher Nerv Syst 2004; 9 (04) 232-241
    CrossrefPubMedGoogle Scholar
  • 72 Do Amaral B, Coelho T, Sousa A, Guimarães A. Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid 2009; 16 (04) 232-238
    CrossrefPubMedGoogle Scholar
  • 73 de Paula Eduardo F, de Mello Bezinelli L, de Carvalho DL. et al. Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy. Neurol Sci 2017; 38 (02) 311-318
    CrossrefPubMedGoogle Scholar
  • 74 Quarta CC, Gonzalez-Lopez E, Gilbertson JA. et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017; 38 (24) 1905-1908
    CrossrefPubMedGoogle Scholar
  • 75 Koike H, Hashimoto R, Tomita M. et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011; 18 (02) 53-62
    CrossrefPubMedGoogle Scholar
  • 76 Obici L, Kuks JB, Buades J. et al; European Network for TTR-FAP (ATTReuNET). Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 2016; 29 (Suppl 1, Suppl 1) S27-S35
    CrossrefPubMedGoogle Scholar
  • 77 Cortese A, Vegezzi E, Lozza A. et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 2017; 88 (05) 457-458
    CrossrefPubMedGoogle Scholar
  • 78 Kapoor M, Rossor AM, Jaunmuktane Z, Lunn MPT, Reilly MM. Diagnosis of amyloid neuropathy. Pract Neurol 2019; 19 (03) 250-258
    CrossrefPubMedGoogle Scholar
  • 79 Planté-Bordeneuve V, Ferreira A, Lalu T. et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007; 69 (07) 693-698
    CrossrefPubMedGoogle Scholar
  • 80 Adams D, Cauquil C, Labeyrie C, Beaudonnet G, Algalarrondo V, Théaudin M. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies. Expert Opin Pharmacother 2016; 17 (06) 791-802
    CrossrefPubMedGoogle Scholar
  • 81 Obici L, Suhr OB. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clin Auton Res 2019; 29 (Suppl. 01) 55-63
    CrossrefPubMedGoogle Scholar
  • 82 Bentellis I, Amarenco G, Gamé X. et al. Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis. Clin Auton Res 2019; 29 (Suppl. 01) 65-74
    CrossrefPubMedGoogle Scholar
  • 83 Gonzalez-Duarte A. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res 2019; 29 (02) 245-251
    CrossrefPubMedGoogle Scholar
  • 84 Marques N, Azevedo O, Almeida AR. et al. Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations. J Am Heart Assoc 2020; 9 (19) e016614
    CrossrefPubMedGoogle Scholar
  • 85 Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 73 (22) 2872-2891
    CrossrefPubMedGoogle Scholar
  • 86 Ando Y, Adams D, Benson MD. et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 2022; 29 (03) 143-155
    CrossrefPubMedGoogle Scholar
  • 87 Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 2015; 21 (03) 282-292
    CrossrefPubMedGoogle Scholar
  • 88 Holmgren G, Steen L, Ekstedt J. et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991; 40 (03) 242-246
    CrossrefPubMedGoogle Scholar
  • 89 Bittencourt PL, Couto CA, Farias AQ, Marchiori P, Bosco Massarollo PC, Mies S. Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil. Liver Transpl 2002; 8 (01) 34-39
    CrossrefPubMedGoogle Scholar
  • 90 Holmgren G, Ericzon BG, Groth CG. et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341 (8853): 1113-1116
    CrossrefPubMedGoogle Scholar
  • 91 Suhr OB, Holmgren G, Steen L. et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995; 60 (09) 933-938
    CrossrefPubMedGoogle Scholar
  • 92 Ericzon BG, Wilczek HE, Larsson M. et al. Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?. Transplantation 2015; 99 (09) 1847-1854
    CrossrefPubMedGoogle Scholar
  • 93 Beirão JM, Malheiro J, Lemos C. et al. Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid 2015; 22 (01) 31-35
    CrossrefPubMedGoogle Scholar
  • 94 Yerevanian AI, Shu F. Pearls & Oy-sters: Number, Weaker, and Dizzier Due to Transthyretin Amyloidosis After 2 Liver Transplants. Neurology 2021; 96 (07) e1088-e1091
    CrossrefPubMedGoogle Scholar
  • 95 Coelho T, Merlini G, Bulawa CE. et al. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther 2016; 5 (01) 1-25
    CrossrefPubMedGoogle Scholar
  • 96 Waddington Cruz M, Benson MD. A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis. Neurol Ther 2015; 4 (02) 61-79
    CrossrefPubMedGoogle Scholar
  • 97 Coelho T, Maia LF, da Silva AM. et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260 (11) 2802-2814
    CrossrefPubMedGoogle Scholar
  • 98 Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 2016; 23 (03) 178-183
    CrossrefPubMedGoogle Scholar
  • 99 Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis 2018; 13 (01) 225
    CrossrefPubMedGoogle Scholar
  • 100 Barroso FA, Judge DP, Ebede B. et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 2017; 24 (03) 194-204
    CrossrefPubMedGoogle Scholar
  • 101 Merlini G, Planté-Bordeneuve V, Judge DP. et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 2013; 6 (06) 1011-1020
    CrossrefPubMedGoogle Scholar
  • 102 Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol 2018; 25 (03) 464-468
    CrossrefPubMedGoogle Scholar
  • 103 Coelho T, Inês M, Conceição I, Soares M, de Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 2018; 91 (21) e1999-e2009
    CrossrefPubMedGoogle Scholar
  • 104 Maurer MS, Schwartz JH, Gundapaneni B. et al; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018; 379 (11) 1007-1016
    CrossrefPubMedGoogle Scholar
  • 105 Damy T, Garcia-Pavia P, Hanna M. et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail 2021; 23 (02) 277-285
    CrossrefPubMedGoogle Scholar
  • 106 Whelan CJSP, Dungu J, Pinney J. et al. GJDaHPN. Tolerability of diflunisal therapy in patients with transthyretin amyloidosis. XIIIth International Symposium on Amyloidosis. Abstract OP 56.2012
    Google Scholar
  • 107 Wixner J, Westermark P, Ihse E, Pilebro B, Lundgren HE, Anan I. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition. Amyloid 2019; 26 (sup1): 39-40
    CrossrefPubMedGoogle Scholar
  • 108 Ackermann EJ, Guo S, Booten S. et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012; 19 (Suppl. 01) 43-44
    CrossrefPubMedGoogle Scholar
  • 109 Ackermann EJ, Guo S, Benson MD. et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid 2016; 23 (03) 148-157
    CrossrefPubMedGoogle Scholar
  • 110 Brannagan TH, Wang AK, Coelho T. et al; NEURO-TTR open-label extension investigators. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol 2020; 27 (08) 1374-1381
    CrossrefPubMedGoogle Scholar
  • 111 Coelho T, Ando Y, Benson MD. et al. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurol Ther 2021; 10 (01) 375-389
    CrossrefPubMedGoogle Scholar
  • 112 Suhr OB, Coelho T, Buades J. et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 2015; 10: 109
    CrossrefPubMedGoogle Scholar
  • 113 Adams D, Polydefkis M, González-Duarte A. et al; patisiran Global OLE study group. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol 2021; 20 (01) 49-59
    CrossrefPubMedGoogle Scholar
  • 114 Habtemariam BA, Karsten V, Attarwala H. et al. Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin Pharmacol Ther 2021; 109 (02) 372-382
    CrossrefPubMedGoogle Scholar
  • 115 Obici L, Cortese A, Lozza A. et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012; 19 (Suppl. 01) 34-36
    CrossrefPubMedGoogle Scholar
  • 116 Gillmore JD, Gane E, Taubel J. et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med 2021; 385 (06) 493-502
    CrossrefPubMedGoogle Scholar
  • 117 Suhr OGM, Da Silva AM, Karam CY. et al. Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 emerging science abstracts. 2021 Emerging Science Abstracts. Neurology 2021; 96: e2783-e2788
    Google Scholar
  • 118 Monteiro C, Mesgazardeh JS, Anselmo J. et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight 2019; 4 (12) 4
    CrossrefPubMedGoogle Scholar